Suastika Ketut, Eliana Fatimah, Kshanti Ida Ayu Made, Mardianto Mardianto, Mudjarnako Sony Wibisono, Natalia Nanny, Hs Heri Nugrohom, Sibarani Roy Panusunan, Soewondo Pradana, Soelistijo Soebagijo Adi, Tarigan Tri Juli Edi, Zufry Hendra
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah Hospital Denpasar, Bali, Indonesia.
Faculty of Medicine, Yarsi University, Jakarta, Indonesia.
Diabetes Metab Syndr Obes. 2022 Sep 27;15:2977-2990. doi: 10.2147/DMSO.S367153. eCollection 2022.
Indonesia is struggling with a rapidly growing burden of diabetes due to rapid socioeconomic transition. People with type 2 diabetes mellitus (T2DM) need appropriate treatment strategies to maintain glycemic control. New modalities with simplicity, such as fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA), further referred to as FRC, have proven to be an effective and practical therapeutic approach that may address this issue. In January 2021, a scientific expert meeting was held with the participation of endocrinologists from Indonesia to provide expert opinions regarding the optimal practical use of the FRC basal insulin/GLP1-RA. Topics discussed in the meeting included the challenges in diabetes management, clinical inertia with insulin therapy, local and international guideline positioning, initiation, titration, and switching of basal insulin and GLP-1 RA, including FRC, and the management of T2DM.
由于社会经济的快速转型，印度尼西亚正面临着糖尿病负担迅速加重的问题。2型糖尿病（T2DM）患者需要适当的治疗策略来维持血糖控制。新的简便治疗方式，如基础胰岛素与胰高血糖素样肽-1受体激动剂（GLP-1 RA）的固定比例联合用药（以下简称FRC），已被证明是一种有效且实用的治疗方法，或许可以解决这一问题。2021年1月，印度尼西亚的内分泌学家参与召开了一次科学专家会议，就FRC基础胰岛素/GLP-1 RA的最佳实际应用提供专家意见。会议讨论的主题包括糖尿病管理中的挑战、胰岛素治疗的临床惰性、国内外指南定位、基础胰岛素和GLP-1 RA（包括FRC）的起始、滴定和转换，以及T2DM的管理。
